(SY1) Symrise - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 10.849m EUR | Total Return: -21.6% in 12m
Avg Turnover: 30.6M
EPS Trend: -5.3%
Rev. Trend: 0.7%
Qual. Beats: 0
Warnings
Extended 1w Choppy
Tailwinds
No distinct edge detected
Symrise AG is a global supplier of fragrances, flavorings, and functional ingredients, operating through two primary segments: Taste, Nutrition & Health, and Scent & Care. Headquartered in Germany, the company services diverse end-markets including food and beverage, pet nutrition, personal care, and pharmaceuticals.
The business model relies on high barriers to entry due to complex regulatory requirements and long-term integration into customers supply chains. As a key player in the specialty chemicals sector, Symrise focuses on research and development to create proprietary aroma molecules and sustainable ingredients.
You may find additional financial metrics and valuation models for Symrise AG on ValueRay.
- Global demand for high-margin pet food ingredients drives nutrition segment growth
- Raw material price volatility impacts gross margins across fragrance and flavor portfolios
- Consumer spending shifts in emerging markets influence volume growth for cosmetic ingredients
- Integration of sustainable and natural ingredients meets tightening European environmental regulations
- Strategic acquisitions in specialized scent markets expand market share and pricing power
| Net Income: 368.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.37 > 1.0 |
| NWC/Revenue: 32.49% < 20% (prev 23.91%; Δ 8.58% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.38b > Net Income 368.7m |
| Net Debt (1.77b) to EBITDA (1.13b): 1.57 < 3 |
| Current Ratio: 2.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.1m) vs 12m ago -2.53% < -2% |
| Gross Margin: 37.93% > 18% (prev 0.38%; Δ 3.75k% > 0.5%) |
| Asset Turnover: 74.81% > 50% (prev 59.34%; Δ 15.47% > 0%) |
| Interest Coverage Ratio: 5.26 > 6 (EBITDA TTM 1.13b / Interest Expense TTM 145.6m) |
| A: 0.25 (Total Current Assets 3.31b - Total Current Liabilities 1.31b) / Total Assets 8.11b |
| B: 0.24 (Retained Earnings 1.93b / Total Assets 8.11b) |
| C: 0.09 (EBIT TTM 765.9m / Avg Total Assets 8.21b) |
| D: 0.35 (Book Value of Equity 1.54b / Total Liabilities 4.36b) |
| Altman-Z'' = 3.39 = A |
| DSRI: 0.95 (Receivables 1.11b/938.1m, Revenue 6.15b/4.94b) |
| GMI: 1.01 (GM 37.93% / 38.38%) |
| AQI: 0.96 (AQ_t 0.40 / AQ_t-1 0.42) |
| SGI: 1.24 (Revenue 6.15b / 4.94b) |
| TATA: -0.12 (NI 368.7m - CFO 1.38b) / TA 8.11b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 77.62 with a total of 455,276 shares traded.
Over the past week, the price has changed by +8.46%,
over one month by +8.45%,
over three months by +7.31% and
over the past year by -21.64%.
Symrise has no consensus analysts rating.
P/E Trailing = 43.6067
P/E Forward = 18.9036
P/S = 2.201
P/B = 2.8461
P/EG = 2.7831
Revenue TTM = 6.15b EUR
EBIT TTM = 765.9m EUR
EBITDA TTM = 1.13b EUR
Long Term Debt = 2.06b EUR (from longTermDebt, last quarter)
Short Term Debt = 417.0m EUR (from shortTermDebt, last quarter)
Debt = 2.78b EUR (from shortLongTermDebtTotal, last quarter) + Leases 168.4m
Net Debt = 1.77b EUR (calculated: Debt 2.78b - CCE 1.01b)
Enterprise Value = 12.6b EUR (10.8b + Debt 2.78b - CCE 1.01b)
Interest Coverage Ratio = 5.26 (Ebit TTM 765.9m / Interest Expense TTM 145.6m)
EV/FCF = 12.57x (Enterprise Value 12.6b / FCF TTM 1.00b)
FCF Yield = 7.96% (FCF TTM 1.00b / Enterprise Value 12.6b)
FCF Margin = 16.34% (FCF TTM 1.00b / Revenue TTM 6.15b)
Net Margin = 6.00% (Net Income TTM 368.7m / Revenue TTM 6.15b)
Gross Margin = 37.93% ((Revenue TTM 6.15b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 33.57% (prev 41.49%)
Tobins Q-Ratio = 1.56 (Enterprise Value 12.6b / Total Assets 8.11b)
Interest Expense / Debt = 5.23% (Interest Expense 145.6m / Debt 2.78b)
Taxrate = 36.32% (144.6m / 398.1m)
NOPAT = 487.7m (EBIT 765.9m * (1 - 36.32%))
Current Ratio = 2.52 (Total Current Assets 3.31b / Total Current Liabilities 1.31b)
Debt / Equity = 0.75 (Debt 2.78b / totalStockholderEquity, last quarter 3.72b)
Debt / EBITDA = 1.57 (Net Debt 1.77b / EBITDA 1.13b)
Debt / FCF = 1.76 (Net Debt 1.77b / FCF TTM 1.00b)
Total Stockholder Equity = 3.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.49% (Net Income 368.7m / Total Assets 8.11b)
RoE = 9.75% (Net Income TTM 368.7m / Total Stockholder Equity 3.78b)
RoCE = 13.11% (EBIT 765.9m / Capital Employed (Equity 3.78b + L.T.Debt 2.06b))
RoIC = 6.84% (NOPAT 487.7m / Invested Capital 7.13b)
WACC = 5.45% (E(10.8b)/V(13.6b) * Re(5.99%) + D(2.78b)/V(13.6b) * Rd(5.23%) * (1-Tc(0.36)))
Discount Rate = 5.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.40 | Cagr: -1.24%
[DCF] Terminal Value 77.97% ; FCFF base≈869.6m ; Y1≈996.8m ; Y5≈1.47b
[DCF] Fair Price = 145.3 (EV 22.1b - Net Debt 1.77b = Equity 20.3b / Shares 139.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -5.33 | EPS CAGR: -2.06% | SUE: N/A | # QB: 0
Revenue Correlation: 0.74 | Revenue CAGR: 0.07% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=3.92 | Chg30d=-0.48% | Revisions=-14% | GrowthEPS=+6.9% | GrowthRev=+0.7%
EPS next Year (2027-12-31): EPS=4.25 | Chg30d=-0.05% | Revisions=-8% | GrowthEPS=+8.2% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -14%